Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Phase II Study of Amprenavir/Ritonavir, Saquinavir/Ritonavir or Efavirenz in HIV-Infected Subjects Following Failure With Kaletra (ABT-378/Ritonavir) as Their First Protease Inhibitor Based HAART

NCT00038532 is registered in ClinicalTrials.gov with Abbott as lead sponsor.

NCT NCT00038532
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00038532 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Phase II Study of Amprenavir/Ritonavir, Saquinavir/Ritonavir or Efavirenz in HIV-Infected Subjects Following Failure With Kaletra (ABT-378/Ritonavir) as Their First Protease Inhibitor Based HAART
Lead sponsor
Abbott
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2001
Completion date
Not reported
Enrollment
24
Sites
54

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infections